Neoplasms, Breast — Brain Metastases In ErbB2-Positive Breast Cancer
Citation(s)
Study EGF107671 - a Phase II Study of Lapatinib Plus Topotecan or Lapatinib Plus Capecitabine in the Treatment of Recurrent Brain Metastases From ErbB2-Positive Breast Cancer Following Cranial Radiotherapy